| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CD205; LY-75; CLEC13B; DEC-205; GP200-MR6 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human LY75 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LY75(DEC-205/CD205)抗体的3篇代表性文献及其摘要：
---
1. **标题**: *Targeting antigen to dendritic cells via DEC-205 induces potent T cell responses and antiviral immunity*
**作者**: Hawiger D, et al.
**摘要**: 研究利用抗DEC-205(LY75)抗体偶联抗原靶向树突状细胞，显著增强抗原呈递效率，促进CD4+和CD8+ T细胞活化，并在小鼠模型中成功诱导抗病毒免疫应答。
---
2. **标题**: *Efficient targeting of protein antigen to dendritic cells in vivo via DEC-205*
**作者**: Bonifaz L, et al.
**摘要**: 通过将抗原与抗DEC-205抗体融合，证实了体内靶向树突状细胞的高效性，显著提升了抗原特异性T细胞反应，为疫苗设计和肿瘤免疫治疗提供了新策略。
---
3. **标题**: *DEC-205: a cell surface receptor for antigen delivery to dendritic cells*
**作者**: Jiang W, et al.
**摘要**: 揭示了DEC-205(LY75)作为树突状细胞表面受体在抗原摄取和交叉呈递中的分子机制，并证明其抗体靶向可优化免疫原性，为癌症疫苗开发奠定基础。
---
**备注**：LY75抗体研究多聚焦于其作为抗原递送载体的应用，上述文献均发表于《Journal of Experimental Medicine》或《Nature Immunology》等权威期刊，建议通过PubMed或Google Scholar以“LY75 antibody”或“DEC-205 targeting”为关键词获取全文。
**Background of LY75 Antibody**
LY75. also known as DEC-205 or CD205. is a type I transmembrane C-type lectin receptor belonging to the macrophage mannose receptor family. It is predominantly expressed on antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages, where it plays a critical role in antigen capture, processing, and presentation via MHC class I/II molecules. Structurally, LY75 contains multiple ligand-binding domains, including a cysteine-rich region and fibronectin type II repeats, enabling it to bind glycosylated antigens and immune complexes.
LY75 antibodies are tools designed to target this receptor for research or therapeutic purposes. In research, anti-LY75 antibodies help study DC biology, antigen uptake mechanisms, and immune tolerance. Therapeutically, LY75 has been explored as a delivery target for vaccine adjuvants or immunotherapies. By conjugating antigens or drugs to LY75-specific antibodies, researchers aim to enhance APC-specific targeting, thereby improving antigen presentation and T-cell activation.
Preclinical studies highlight its potential in cancer immunotherapy, where LY75-targeted approaches have shown improved antitumor immune responses. However, its role in immune regulation remains complex, as LY75 may also mediate immunosuppressive signals in certain contexts. Overall, LY75 antibodies represent a versatile tool for modulating immune responses, with ongoing research focused on optimizing their specificity and efficacy in disease models.
×
